PARK7 and cancer: It should be noted that the covalent, irreversiblenature of JYQ-194 may limit its potency as it cannotbe recycled upon PARK7 degradation, which possibly lowers its efficacyin an in vivo setting.31 Despite its limitation, the creation of JYQ-194 PROTACprovides new opportunities for targeting PARK7 in cancer therapy sincePARK7 is overexpressed in various types of cancer.1,5,48